Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Thailand Shows Early Signs Of Resistance To Basic Malaria Drug

This article was originally published in PharmAsia News

Executive Summary

Thailand once again is showing the world a danger of emerging resistance to a major drug, this time the deadliest form of malaria to artemisinin, the basic ingredient in the leading treatments. Researchers for a recently published study have determined the drug is losing potency in Thailand, signaling a global need for a new generation of drugs. The effort to generate a sense of emergency has been hampered by more recent studies that show there have been relatively no signs of the artemisinin resistance. An area on the Thai border with Cambodia has a history as the starting point for resistance to malaria drugs. (Click here for more

Latest Headlines
See All
UsernamePublicRestriction

Register

SC069960

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel